StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/302% below fair value
$398.08−23.91 (-5.67%)

Close on Nov 18, 2026Market cap $9.20BP/E –Yield –

Madrigal Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Madrigal Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$206.29M. For fiscal 2025 it was -$190.02M. The highest annual figure on record is -$3.20M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$190.02M–
FY2024Dec 31, 2024-$457.03M–
FY2023Dec 31, 2023-$325.71M–
FY2022Dec 31, 2022-$225.07M–
FY2021Dec 31, 2021-$184.13M–
FY2020Dec 31, 2020-$157.90M–
FY2019Dec 31, 2019-$41.80M–
FY2018Dec 31, 2018-$25.53M–
FY2017Dec 31, 2017-$22.44M–
FY2016Dec 31, 2016-$17.61M–
FY2015Dec 31, 2015-$3.20M–
FY2014Dec 31, 2014-$79.07M–
FY2013Dec 31, 2013-$78.18M–
FY2012Dec 31, 2012-$54.64M–
FY2011Dec 31, 2011-$47.99M–
FY2010Dec 31, 2010-$38.34M–
FY2009Dec 31, 2009-$27.26M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.08M–
Q1 FY2026Mar 31, 2026-$171.28M–
Q4 FY2025Dec 31, 2025-$133.07M–
Q3 FY2025Sep 30, 2025$78.99M–
Q2 FY2025Jun 30, 2025-$47.05M–
Q1 FY2025Mar 31, 2025-$88.89M–
Q4 FY2024Dec 31, 2024-$104.68M–
Q3 FY2024Sep 30, 2024-$67.76M–
Q2 FY2024Jun 30, 2024-$135.08M–
Q1 FY2024Mar 31, 2024-$149.51M–
Q4 FY2023Dec 31, 2023-$80.97M–
Q3 FY2023Sep 30, 2023-$85.26M–
Q2 FY2023Jun 30, 2023-$75.38M–
Q1 FY2023Mar 31, 2023-$84.10M–
Q4 FY2022Dec 31, 2022-$58.54M–
Q3 FY2022Sep 30, 2022-$59.10M–
Q2 FY2022Jun 30, 2022-$57.46M–
Q1 FY2022Mar 31, 2022-$49.97M–
Q4 FY2021Dec 31, 2021-$48.16M–
Q3 FY2021Sep 30, 2021-$45.61M–
Q2 FY2021Jun 30, 2021-$46.88M–
Q1 FY2021Mar 31, 2021-$43.47M–
Q4 FY2020Dec 31, 2020-$54.96M–
Q3 FY2020Sep 30, 2020-$47.85M–
Q2 FY2020Jun 30, 2020-$24.27M–
Q1 FY2020Mar 31, 2020-$30.82M–
Q4 FY2019Dec 31, 2019-$12.42M–
Q3 FY2019Sep 30, 2019-$11.32M–
Q2 FY2019Jun 30, 2019-$11.54M–
Q1 FY2019Mar 31, 2019-$6.52M–
Q4 FY2018Dec 31, 2018-$6.27M–
Q3 FY2018Sep 30, 2018-$5.25M–
Q2 FY2018Jun 30, 2018-$5.36M–
Q1 FY2018Mar 31, 2018-$8.65M–
Q4 FY2017Dec 31, 2017-$5.95M–
Q3 FY2017Sep 30, 2017-$4.95M–
Q2 FY2017Jun 30, 2017-$7.77M–
Q1 FY2017Mar 31, 2017-$3.77M–
Q4 FY2016Dec 31, 2016-$5.28M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?